)
Edge29 May 2026
Who You Gonna Call? The Story of Rollins
How Rollins built one of America's most consistent businesses through recurring pest control, trusted local brands, and decades of acquisitions.
Palatin Technologies
Palatin Technologies (PTN) investor relations material
Palatin Technologies Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary29 May, 2026
Technology and expertise
Focus on melanocortin system, specifically MC4R agonists for syndromic and genetic obesity.
First to gain FDA approval for a melanocortin agent (Vyleesi® for female sexual dysfunction).
Demonstrated ability to move programs from discovery to FDA approval.
Strategy leverages deep expertise in melanocortin biology and chemistry.
Leadership and team
Leadership team with over 20–40 years of experience in drug development, finance, legal, and business development.
Extensive backgrounds from major pharma companies and successful track records in R&D and commercialization.
Development pipeline and programs
Developing next-generation MC4R selective agonists as peptides (weekly injection) and oral small molecules (daily dosing) for rare neuroendocrine diseases.
Target indications: hypothalamic obesity (HO), Prader-Willi syndrome (PWS), and Bardet-Biedl syndrome (BBS).
IND filings for peptide and oral programs planned for late 2026 and early 2027, with Phase 1 and 2/3 studies to follow.
MC4R agonism validated as a target for obesity management; high unmet need in target populations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Palatin Technologies
- Advancing selective MC4R agonists for rare obesity, with key clinical and partnership milestones ahead.PTN
Corporate presentation18 May 2026 - Licensing revenue growth and pipeline progress support operations through mid-2027.PTNQ3 202613 May 2026
- MC4R-based obesity pipeline advances with strong cash reserves and key clinical milestones ahead.PTNQ2 202611 Apr 2026
- Advancing MC4R agonists for rare obesity, with strong pipeline and strategic partnerships.PTNCorporate presentation16 Mar 2026
- Advancing MC4R agonists for rare obesity and forging key partnerships for future growth.PTNCorporate presentation17 Feb 2026
- Net loss of $29.7M, asset sale, and pipeline progress set stage for key 2024–2025 milestones.PTNQ4 202419 Jan 2026
- No product revenue, $7.8M net loss, and a strategic pivot to obesity programs with key data due in 2025.PTNQ1 202514 Jan 2026
- Net loss narrowed, no product revenue, and liquidity risks persist amid advancing clinical programs.PTNQ2 202524 Dec 2025
- Shareholders to vote on director elections, reverse split, warrants, and executive pay.PTNProxy Filing1 Dec 2025
Next Palatin Technologies earnings date
Q4 202618 Sep, 2026
Palatin Technologies
Next Palatin Technologies earnings date
Q4 202618 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage